Is an electronic signature valid?

Yes. Under the Federal ESIGN Act (15 U.S.C. §7001) and most states' UETA statutes, electronic signatures are legally equivalent to handwritten signatures when intent, consent, attribution, and retention requirements are satisfied.

Will FDA accept electronically signed letters?

FDA accepts electronic records for regulated activities, but when records support regulatory decisions ensure compliance with 21 CFR Part 11 requirements for electronic records and signatures, including audit trails, system validation, and restricted access controls.

Is notarization or witnessing required?

Not typically. FDA correspondence rarely requires notarization. Notarization and witness rules are state-specific for legal documents; use RON only if state law and contractual requirements call for notarized records or when a third party explicitly requests it.

Can I e-file this letter?

Filing routes depend on recipient requirements. Internally, upload to validated repositories. To submit to FDA or public dockets, follow agency submission channels such as eSubmitter or eRMS when required; always preserve original signed PDF and audit trail.

Who should sign the letter?

An authorized corporate officer or designated regulatory representative with documented authority should sign. For sponsors, the signer typically is the head of regulatory affairs or a corporate officer whose signature is recognized in company delegation of authority policies.

How long to retain records?

Maintain approval letters and supporting records according to applicable retention rules: at least three years for federal tax/financial records (IRC §6501(a)), six years for HIPAA-related documents (45 CFR §164.530(j)), and longer where state or industry rules apply.

Electronic Signature
Templates
Legal
Legal FDA Approval Letter

Legal FDA Approval Letter

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

LEGAL FDA APPROVAL LETTER

This Legal FDA Approval Letter (the "Letter") is made as of by and between Client Name: with principal place of business at ("Sponsor"), and Client Name: with principal place of business at ("Recipient").

RECITALS

WHEREAS, Sponsor has submitted to the United States Food and Drug Administration an application for marketing authorization for the product identified as Product Name: (the "Product"); and

WHEREAS, the FDA issued approval identified by Approval No.: on (the "Approval"); and

WHEREAS, Sponsor and Recipient desire to set forth the conditions under which the Approval and related regulatory representations are being communicated for commercial, labeling and distribution purposes.

NOW THEREFORE

In consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. DEFINITIONS

For purposes of this Letter, the following terms have the meanings set forth below: "Approval" means the FDA authorization described above; "Labeling" means all written, printed or graphic matter accompanying or made part of the Product, including instructions for use and marketing materials; "Territory" means .

2. DECLARATION OF APPROVAL

Sponsor hereby certifies that, as of the Approval date set forth above, the Product has received regulatory approval from the FDA for the indications and labeling set forth in Sponsor's approval documentation. Sponsor represents that to the best of its knowledge the Approval is in full force and effect and that no order, stay, suspension or withdrawal of the Approval is pending or threatened.

3. SCOPE AND CONDITIONS OF USE

Recipient may rely on Sponsor's representation of Approval solely for the Product specified in Section 1 and only for the uses expressly set forth in the approved Labeling. Recipient shall not market, label, promote, distribute or modify the Product in any manner inconsistent with the approved Labeling or the limitations set forth by the FDA.

Any change to the Product, manufacturing process, packaging or labeling that may affect safety, efficacy or regulatory compliance shall require prior written notice to Sponsor and, if required by applicable law, an amendment to the Approval. Recipient shall cease distribution of the Product upon notice from Sponsor of any material change in regulatory status.

4. REPRESENTATIONS AND WARRANTIES

Sponsor represents and warrants that: (a) it is the holder of the Approval or is authorized to disclose the Approval to the Recipient for the purposes described herein; (b) to the best of Sponsor's knowledge, the Approval is valid and not subject to unresolved material compliance actions; and (c) Sponsor has provided Recipient with true and complete copies of the approved Labeling and material regulatory correspondence relevant to the Approval.

EXCEPT AS SET FORTH IN THIS SECTION, THE APPROVAL IS PROVIDED "AS IS" AND SPONSOR MAKES NO FURTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

5. INDEMNIFICATION

Each party (the "Indemnifying Party") shall indemnify, defend and hold harmless the other party and its directors, officers, employees and agents (the "Indemnified Party") from and against any and all third-party claims, liabilities, losses, damages, costs and expenses (including reasonable attorneys' fees) arising out of or resulting from: (a) the Indemnifying Party's breach of its representations, warranties or obligations under this Letter; or (b) the Indemnifying Party's negligent or willful misconduct in connection with the manufacture, marketing or distribution of the Product.

6. CONFIDENTIALITY

The parties acknowledge that regulatory correspondence, Labeling drafts, study reports and terms of this Letter may constitute confidential information. Each party shall maintain such information in confidence and shall not disclose it to any third party except as required by law or regulatory authority, subject to advance notice to the other party where practicable.

7. NOTIFICATIONS OF ADVERSE EVENTS AND REGULATORY ACTIONS

Each party shall promptly notify the other in writing of any material regulatory action, adverse event, recall, inspectional observation or other event that may materially affect the safety, efficacy or continued approval of the Product. Notification shall be provided in accordance with the Notices provision below.

8. LIMITATION OF LIABILITY

EXCEPT FOR LIABILITY ARISING FROM A PARTY'S GROSS NEGLIGENCE, WILLFUL MISCONDUCT, OR INDEMNIFICATION OBLIGATIONS, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGES ARISING UNDER THIS LETTER.

9. TERM AND TERMINATION

This Letter shall become effective on the Effective Date above and shall remain in effect until the Approval is withdrawn or otherwise terminated by Sponsor or by operation of law. Either party may terminate this Letter for cause upon thirty (30) days' written notice if the other party materially breaches any provision and fails to cure within the notice period.

10. NOTICES

Sponsor Notice Address

Recipient Notice Address

All notices required or permitted under this Letter shall be in writing and delivered to the addresses set forth above by hand, certified mail, or overnight courier and shall be deemed given upon receipt.

11. AMENDMENTS; WAIVER; COUNTERPARTS

This Letter may be amended only by a written instrument executed by authorized representatives of both parties. No waiver of any provision shall be effective unless in writing and signed by the party waiving compliance. This Letter may be executed in counterparts, each of which shall constitute an original.

12. GOVERNING LAW; SEVERABILITY; ENTIRE AGREEMENT

This Letter shall be governed by and construed in accordance with the laws of the State of , without regard to its conflicts of law principles. If any provision of this Letter is held invalid or unenforceable, the remaining provisions shall remain in full force and effect. This Letter, together with any attachments or regulatory documents expressly incorporated by reference, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements and understandings.

ATTACHMENTS

Attached hereto and incorporated herein by reference are: (a) a true and complete copy of the FDA Approval documentation; (b) the approved Labeling; and (c) material regulatory correspondence relevant to the Approval. Describe other attachments or specifications below.

Describe Attachments / Specifications

Sponsor:

By:

Date:

Recipient:

By:

Date:

What a Legal FDA Approval Letter Is and Why It Matters

A Legal FDA Approval Letter is a formal, written communication that documents the U.S. Food and Drug Administration's authorization, clearance, or determination regarding a medical product, device, drug, or related regulated activity. It serves as official evidence that the FDA has completed its review and has granted the specific regulatory status described in the letter, including any conditions, limitations, or required post-market actions. Organizations use this letter to confirm compliance, update labeling and promotional materials, fulfill contractual or procurement obligations, and to notify stakeholders and partners of the product's regulatory standing.

Practical Role of the Approval Letter in Compliance and Contracts

A Legal FDA Approval Letter clarifies regulatory status, supports lawful marketing claims, and documents conditions the FDA may impose. It streamlines internal compliance checks, informs contract performance, and provides a clear record for auditors, legal counsel, distributors, and downstream stakeholders.

Who Prepares, Reviews, and Relies on the Letter

Organizations that prepare or rely on an FDA approval letter include manufacturers, regulatory affairs teams, legal counsel, and contracting parties.

Medical device and pharmaceutical manufacturers who submit regulatory applications and need formal agency correspondence.
Regulatory affairs or quality teams tracking compliance, labeling, and post-market requirements tied to approval.
Legal departments, procurement, and distributors using the letter to confirm contract conditions and claims.

The letter also matters to investors, insurers, and clinical sites that require documented FDA determinations for risk and compliance assessments.

Core Elements to Include in a Professional Approval Letter

A professional Legal FDA Approval Letter should be precise, legally clear, and include references to the specific submission, decision, and any required follow-up actions.

Letterhead

Official FDA letterhead or identifying header with date, correspondence ID, and the issuing office or division to aid verification and traceability and include contact information for follow-up.

Decision

Clear statement of approval, clearance, or denial, including the legal basis (e.g., 510(k), PMA, NDA), conditions, and any limitations on use and specific references to application numbers and submission dates for the relevant file.

Scope

Description of approved indications, patient populations, manufacturing sites, and device versions or formulations covered by the determination to prevent misinterpretation and any labeling or promotional claim restrictions.

Conditions

Any post-approval requirements, such as post-market surveillance, adverse event reporting, or periodic safety updates, with timelines and responsible parties specified including submission frequencies, contact points, and documentation format expectations.

Signature

Authorized signature block naming the official signer, title, date, and a machine-readable signature or typed name; notarization rarely required but noted if present and include contact information for verification.

References

Cross-references to the original submission, relevant guidance documents, CFR sections, and instructions for appeals or administrative follow-up including citations to 21 CFR parts, FDA guidance titles, and contact channels for procedural questions.

Required Identifying Information and Fields

Application ID: Submission number as listed in FDA records

Product Name: Exact product or device trade and model name

Applicant Entity: Legal name of manufacturer or sponsor

Decision Type: Approval, clearance, denial, or letter type

Effective Date: MM/DD/YYYY format as the official start

Conditions: Any post-market obligations or limitations listed

Step-by-Step: Prepare and Issue the Letter

Follow this sequence to prepare, validate, and distribute a Legal FDA Approval Letter with audit-ready documentation and regulatory traceability.

01

Gather Records: Collect submission files, correspondence, and reference documents for accuracy.
02

Draft Letter: Use precise regulatory language and cite application numbers.
03

Internal Review: Regulatory and legal teams confirm wording and conditions.
04

Distribute: Send signed copy to recipients, retain audit trail, and archive.

How to Configure an Online Template for the Letter

Configure an online template for the Legal FDA Approval Letter with fields, conditional logic, signer roles, and automated storage for audit compliance.

Field	Configuration
Template Name	Use standard title including application number
Signer Role	Assign regulatory signer and secondary witness as needed
Conditional Fields	Show conditions section only if approval includes post-market requirements
Audit Trail	Enable full audit trail with timestamps and IP addresses
Archive Location	Save to secured folder with versioning and access controls

Where to Send or File the Final Letter

Typical delivery paths for an FDA approval letter include sending to internal stakeholders, regulatory repositories, contracting partners, and uploading to secure record systems.

Internal Records: Store in regulatory affairs and quality management systems for compliance.
Contract Partners: Provide signed letter to distributors, payors, or procurement contacts.
Public Docket: When required, reference or submit to the FDA public docket or eRMS.
Regulatory Archive: Archive final PDF and metadata per retention policy with audit trail.

Technical Requirements for Digital Distribution and Signing

Digital delivery requires compatibility with e-signature and secure storage platforms, plus attention to authentication and PDF standards.

File Formats: PDF | DOCX | XML supported
Integrations: Salesforce, NetSuite, Google Workspace, Microsoft 365
Security: TLS 1.2/1.3 and AES-256 encryption

Key Timing and Deadlines to Track

Key timing checkpoints for using or responding to an FDA approval letter, plus downstream deadlines for labeling and contractual obligations.

Issuance Date:

Letter date establishes effective date and triggers labeling updates.

Labeling Updates:

Update labels within timeframes specified or immediately upon effective date.

Contract Notices:

Notify partners within contractually required notice periods; check agreements for specifics.

Post-market Reports:

Submit surveillance or adverse event reports per letter timelines and 21 CFR rules.

Record Retention:

Retain letter and supporting documents per regulatory and internal retention policy.

Common Preparation and Formatting Errors to Avoid

Using informal or nonstandard wording that conflicts with FDA terminology can cause legal ambiguity and impede regulatory acceptance; always mirror the agency's language precisely.
Failing to include application identifiers, decision dates, or issuing office details makes verification difficult and may delay commercial or contractual actions tied to approval.
Neglecting to capture a complete audit trail when using electronic signatures undermines evidentiary value and can affect enforceability under ESIGN and 21 CFR Part 11.
Assuming notarization is required for FDA correspondence; notarization is rarely necessary and adding it without reason creates unnecessary costs and processing delays.

Consequences of Incorrect or Misleading Letters

Regulatory Action: Warning letters, seizures, injunctions

Civil Liability: Contract breaches or damages claims

Criminal Exposure: False statements risk federal prosecution

Contract Remedies: Termination, indemnities, damages

Tax/Payment Issues: Withholding or payment suspension

Reputational Harm: Loss of market trust

Comparison: eSignature Vendors for Regulated Letters

A concise comparison of common eSignature vendors for handling FDA approval letters and regulated records.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	Varies by plan	Varies by plan	Varies by plan	Varies by plan
Bulk Send	Available on paid tier	Varies by plan	Varies by plan	Varies by plan	Varies by plan
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Verify vendor	Verify vendor	Verify vendor	Verify vendor
Envelope Cap	No cap	100 envelopes/user/year	Varies	Varies	Varies

FAQs and Troubleshooting for Legal FDA Approval Letters

Answers to frequent questions about preparing, signing, and storing a Legal FDA Approval Letter, including e-signature validity and recordkeeping.

Need help? Contact support

Is an electronic signature valid?
Yes. Under the Federal ESIGN Act (15 U.S.C. §7001) and most states' UETA statutes, electronic signatures are legally equivalent to handwritten signatures when intent, consent, attribution, and retention requirements are satisfied.
Will FDA accept electronically signed letters?
FDA accepts electronic records for regulated activities, but when records support regulatory decisions ensure compliance with 21 CFR Part 11 requirements for electronic records and signatures, including audit trails, system validation, and restricted access controls.
Is notarization or witnessing required?
Not typically. FDA correspondence rarely requires notarization. Notarization and witness rules are state-specific for legal documents; use RON only if state law and contractual requirements call for notarized records or when a third party explicitly requests it.
Can I e-file this letter?
Filing routes depend on recipient requirements. Internally, upload to validated repositories. To submit to FDA or public dockets, follow agency submission channels such as eSubmitter or eRMS when required; always preserve original signed PDF and audit trail.
Who should sign the letter?
An authorized corporate officer or designated regulatory representative with documented authority should sign. For sponsors, the signer typically is the head of regulatory affairs or a corporate officer whose signature is recognized in company delegation of authority policies.
How long to retain records?
Maintain approval letters and supporting records according to applicable retention rules: at least three years for federal tax/financial records (IRC §6501(a)), six years for HIPAA-related documents (45 CFR §164.530(j)), and longer where state or industry rules apply.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now